Stable Gross MarginsConsistently stable gross margins point to durable cost controls and pricing resilience in Bal Pharma's manufacturing base. For 2–6 months this supports predictable gross profitability, helping absorb selling and overhead variability and underpinning core earnings even if top-line growth lags.

Improving ROEAn improving ROE signals more effective use of equity capital and operational leverage. Over the medium term, rising ROE suggests management is generating higher returns from invested capital, which can support reinvestment capacity and shareholder value creation despite industry cyclicality.

Diversified Business Lines (Formulations & APIs)Operating across formulations and API manufacturing provides structural diversification of revenue and customer types. This multi-channel model reduces dependency on a single market or product, supports cross-utilization of manufacturing capacity, and provides multiple routes for sustained revenue and margin recovery.

Bears Say

High LeverageSignificant leverage constrains financial flexibility and raises interest burden risk. Over months, elevated debt limits ability to fund capex, R&D, or weather revenue shortfalls, increasing refinancing and solvency risk in an industry that can require timely regulatory or capacity investments.

Inconsistent Cash GenerationVolatile operating and free cash flow undermine liquidity and the firm's capacity to self-fund operations or strategic investments. Sustained inconsistency increases reliance on external financing, complicates working capital management, and raises the chance of interrupted supply or delayed product launches.

Negative Recent Revenue GrowthA recent decline in revenue reduces scale benefits and strains margin conversion. Persisting negative top-line momentum pressures fixed-cost absorption and heightens operational risk; reversing this trend is essential for durable margin improvement and to stabilize cash generation.

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹64.00 and its highest was ₹128.86 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.26B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 99 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on Feb 11, 2026. The company reported ₹1.118 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.118.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.62%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹1.118 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.072%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.